New Concepts in Chronic Obstructive Pulmonary Disease

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 113-129

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Bronchitis; Emphysema; Inflammation; Macrophage; Proteases

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE; CIGARETTE SMOKE; CORTICOSTEROID; CYTOKINE; GROWTH FACTOR; LIPID; MATRIX METALLOPROTEINASE; PHOSPHODIESTERASE IV INHIBITOR; AUTACOID;

AIRWAY; ASTHMA; CAUSE OF DEATH; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISABILITY; ELASTOLYSIS; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS WALL; LUNG EMPHYSEMA; MEDIATOR RELEASE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIDE EFFECT; DISEASE COURSE; IMMUNOLOGY; METABOLISM;

DISEASE PROGRESSION; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGES, ALVEOLAR; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0012626868     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152209     Document Type: Review

References (103)

1. Lopez AD, Murray CC. 1998. The global burden of disease, 1990-2020. Nat. Med. 4:1241-43
2. Barnes PJ. 2000. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343:269-80
3. Barnes PJ. 2001. New treatments for chronic obstructive pulmonary disease. Curr. Opin. Pharmacol. 1:217-22
4. Barnes PJ. 2002. New treatments for COPD. Nat. Rev. Drug Disc. 1:437-45
5. Pauwels RA, Buist AS, Calverley PM, et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Resp. Crit. Care Med. 163:1256-76
6. Barnes PJ. 2000. Mechanisms in COPD: differences from asthma. Chest 117:10S-4S
7. Saetta M, Turato G, Maestrelli P, et al. 2001. Cellular and structural bases of chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 163:1304-9
8. + T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 157:822-26
9. Di Stefano A, Capelli A, Lusuardi M, et al. 1998. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Resp. Crit. Care Med. 158:1277-85
10. Pesci A, Balbi B, Majori M, et al. 1998. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Resp. J. 12:380-86
11. Keatings VM, Collins PD, Scott DM, Barnes PJ. 1996. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Resp. Crit. Care Med. 153:530-34
12. Fabbri L, Beghe B, Caramori G, et al. 1998. Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax 53:803-8
13. Lacoste JY, Bousquet J, Chanez P. 1993. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 92:537-48
14. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. 1995. Alveolar inflammation and its relation to emphysema in smokers. Am. J. Resp. Crit. Care Med. 152:1666-72
15. Di Stefano A, Maestrelli P, Roggeri A, et al. 1994. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am. J. Resp. Crit. Care Med. 149:803-10
16. Meshi B, Vitalis TZ, Ionescu D, et al. 2002. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am. J. Resp. Cell Mol. Biol. 26:52-57
17. Russell REK, Thorley A, Culpitt SV, et al. 2002. Alveolar macrophage mediated elastolysis: roles of matrix metalloproteinases, cysteine and serine proteases. Am. J. Physiol. Lung Cell Mol. Physiol. 283:L867-L73
18. L expression and reduced apoptosis in alveolar macrophages from smokers. Am. J. Resp. Crit. Care Med. 166:724-31
19. Majo J, Ghezzo H, Cosio MG. 2001. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur. Resp. J. 17:946-53
20. +ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 160:711-17
21. 1. Am. J. Resp. Crit. Care Med. 155:852-57
22. Hashimoto S, Kobayashi A, Kooguchi K, et al. 2000. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 161:237-43
23. Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, et al. 2000. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 95:231-40
24. Turato G, Zuin R, Saetta M. 2001. Pathogenesis and pathology of COPD. Respiration 68:117-28
25. Brightling CE, Monteiro W, Ward R, et al. 2000. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356:1480-85
26. Papi A, Romagnoli M, Baraldo S, et al. 2000. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 162:1773-77
27. Saetta M, Di Stefano A, Maestrelli P, et al. 1994. Airway eosinophilia in chronic bronchitis during exacerbations. Am. J. Resp. Crit. Care Med. 150:1646-52
28. Saetta M, Di Stefano A, Maestrelli P, et al. 1996. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin. Exp. Allergy 26:766-74
29. Keatings VM, Barnes PJ. 1997. Granulocyte activation markers in induced sputum: comparison between COPD, asthma and normal subjects. Am. J. Resp. Crit. Care Med. 155:449-53
30. Liu H, Lazarus SC, Caughey GH, Fahy JV. 1999. Neutrophil elastase and elastaserich cystic fibrosis sputum degranulate human eosinophils in vitro. Am. J. Physiol. Lung Cell Mol. Physiol. 276:L28-L34
31. Takizawa H, Tanaka M, Takami K, et al. 2001. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with COPD. Am. J. Resp. Crit. Care Med. 163:1476-83
32. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. 2000. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 106:1311-19
33. Hill AT, Bayley D, Stockley RA. 1999. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. J. Resp. Crit. Care Med. 160:893-98
34. Repine JE, Bast A, Lankhorst I. 1997. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 156:341-57
35. Macnee W. 2001. Oxidative stress and lung inflammation in airways disease. Eur. J. Pharmacol. 429:195-207
36. Dekhuijzen PNR, Aben KHH, Dekker I, et al. 1996. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 154:813-16
37. Montuschi P, Collins JV, Ciabattoni G, et al. 2000. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Resp. Crit. Care Med. 162:1175-77
38. Paredi P, Kharitonov SA, Leak D, et al. 2000. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 162:369-73
39. Ichinose M, Sugiura H, Yamagata S, et al. 2000. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am. J. Resp. Crit. Care Med. 160:701-6
40. Yamamoto C, Yoneda T, Yoshikawa M, et al. 1997. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 112:505-10
41. Traves SL, Culpitt S, Russell REK, et al. 2002. Increased levels of the chemokines GRO-α and MCP-1 in sputum samples from patients with COPD. Thorax 57:590-95
42. Capelli A, Di Stefano A, Gnemmi I, et al. 1999. Increased MCP-1 and MIP-1β in bronchoalveolar lavage fluid of chronic bronchitis. Eur. Resp. J. 14:160-65
43. Aaron SD, Angel JB, Lunau M, et al. 2001. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 163:349-55
44. de Godoy I, Donahoe M, Calhoun WJ, et al. 1996. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Resp. Crit. Care Med. 153:633-37
45. Langen RC, Schols AM, Kelders MC, et al. 2001. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-κB. FASEB J. 15:1169-80
46. Barnes PJ. 2001. Cytokine modulators as novel therapies for airway disease. Eur. Resp. J. 18:67S-77S
47. Balbi B, Bason C, Balleari E, et al. 1997. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur. Resp. J. 10:846-50
48. de Boer WI, van Schadewijk A, Sont JK, et al. 1998. Transforming growth factor β1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 158:1951-57
49. Zheng T, Zhu Z, Wang Z, et al. 2000. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase-and cathepsin-dependent emphysema. J. Clin. Invest. 106:1081-93
50. Wang Z, Zheng T, Zhu Z, et al. 2000. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J. Exp. Med. 192:1587-600
51. Chalmers GW, Macleod KJ, Sriram S, et al. 1999. Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. Eur. Resp. J. 13:1288-92
52. Roland M, Bhowmik A, Sapsford RJ, et al. 2001. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 56:30-35
53. Giaid A, Yanagisawa M, Langleben D, et al. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328:1732-39
54. Gottlieb DJ, Stone PJ, Sparrow D, et al. 1996. Urinary desmosine excretion in smokers with and without rapid decline of lung function. Am. J. Resp. Crit. Care Med. 154:1290-95
55. Stockley RA. 1999. Neutrophils and protease/antiprotease imbalance. Am. J. Resp. Crit. Care Med. 160:S49-S52
56. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. 1999. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am. J. Resp. Cell Mol. Biol. 20:729-36
57. Shapiro SD, Senior RM. 1999. Matrix metalloproteinases. Matrix degradation and more. Am. J. Resp. Cell Mol. Biol. 20:1100-2
58. Finlay GA, O'Driscoll LR, Russell KJ, et al. 1997. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Resp. Crit. Care Med. 156:240-47
59. Culpitt SV, Nightingale JA, Barnes PJ. 1999. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 160:1635-39
60. Betsuyaku T, Nishimura M, Takeyabu K, et al. 1999. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am. J. Resp. Crit. Care Med. 159:1985-91
61. Ohnishi K, Takagi M, Kurokawa Y, et al. 1998. Matrix metalloproteinase- mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. 78:1077-87
62. Lim S, Roche N, Oliver BG, et al. 2000. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers, regulation by interleukin-10. Am. J. Resp. Crit. Care Med. 162:1355-60
63. Russell REK, Culpitt SV, de Matos C, et al. 2002. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with COPD. Am. J. Resp. Cell Mol. Biol. 26:602-9
64. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. 1997. Requirement for macrophage metalloelastase for cigarette smoke-induced emphysema in mice. Science 277:2002-4
65. Punturieri A, Filippov S, Allen E, et al. 2000. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J. Exp. Med. 192:789-800
66. Barnes PJ. 1999. Molecular genetics of chronic obstructive pulmonary disease. Thorax 54:245-52
67. 10-induced transcription of interleukin-8. Am. J. Physiol. Lung Cell Mol. Physiol. 281:L598-L606
68. Ito K, Barnes PJ, Adcock IM. 2000. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1β-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell Biol. 20:6891-903
69. Ito K, Lim S, Caramori G, et al. 2001. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 15:1100-2
70. Ito K, Watanabe S, Kharitonov S, et al. 2001. Histone deacetylase activity and gene expression in COPD patients. Eur. Resp. J. 18:316S (Abstr.)
71. Di Stefano A, Caramori G, Capelli A, et al. 2002. Increased expression of NF-κB in bronchial biopsies from smokers and patients with COPD. Eur. Resp. J. 18: In press
72. Casolari P, Caramori G, Bellettato C, et al. 2002. Differential activation of p65 protein in alveolar macrophages and neutrophils in COPD sputum: effect of exacerbation. Am. J. Respir. Crit. Care Med. 165:A597 (Abstr.)
73. Turato G, Di Stefano A, Maestrelli P, et al. 1995. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am. J. Respir. Crit. Care Med. 152:1262-67
74. Rutgers SR, Postma DS, ten Hacken NH, et al. 2000. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55:12-18
75. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. 1997. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 155:542-48
76. Loppow D, Schleiss MB, Kanniess F, et al. 2001. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir. Med. 95:115-21
77. Meagher LC, Cousin JM, Seckl JR, Haslett C. 1996. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156:4422-28
78. Nightingale JA, Rogers DF, Chung KF, Barnes PJ. 2000. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am. J. Respir. Crit. Care Med. 161:479-86
79. Tashkin DP, Altose MD, Connett JE, et al. 1996. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am. J. Respir. Crit. Care Med. 153:1802-11
80. Vestbo J, Sorensen T, Lange P, et al. 1999. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353:1819-23
81. Pauwels RA, Lofdahl CG, Laitinen LA, et al. 1999. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 340:1948-53
82. Burge PS, Calverley PMA, Jones PW, et al. 2000. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. BMJ 320:1297-303
83. Lung Health Study Research Group. 2000. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 343:1902-9
84. Paggiaro PL, Dahle R, Bakran I, et al. 1998. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 351: 773-80
85. Barnes PJ. 2000. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 161:342-44
86. Yamada K, Elliott WM, Brattsand R, et al. 2002. Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation. J. Allergy Clin. Immunol. 109:35-42
87. Niewoehner DE, Erbland ML, Deupree RH, et al. 1999. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 340:1941-47
88. Davies L, Angus RM, Calverley PM. 1999. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354:456-60
89. Seemungal TA, Donaldson GC, Paul EA, et al. 1998. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157:1418-22
90. Seemungal T, Harper-Owen R, Bhowmik A, et al. 2001. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164:1618-23
91. Donaldson GC, Seemungal T, Jeffries DJ, Wedzicha JA. 1999. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur. Respir. J. 13:844-49
92. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. 2000. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 55:114-20
93. Crooks SW, Bayley DL, Hill SL, Stockley RA. 2000. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur. Respir. J. 15:274-80
94. Maziak W, Loukides S, Culpitt S, et al. 1998. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157:998-1002
95. Agusti AG, Villaverde JM, Togores B, Bosch M. 1999. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 14:523-28
96. Noguera A, Busquets X, Sauleda J, et al. 1998. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158:1664-68
97. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. 1996. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51:819-24
98. Schols AM, Slangen J, Volovics L, Wouters EF. 1998. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157:1791-97
99. Schols AM, Creutzberg EC, Buurman WA, et al. 1999. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160:1220-26
100. Eid AA, Ionescu AA, Nixon LS, et al. 2001. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164:1414-18
101. Bernard S, Leblanc P, Whittom F, et al. 1998. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158:629-34
102. Schols AM, Soeters PB, Mostert R, et al. 1995. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am. J. Respir. Crit. Care Med. 152:1268-74
103. Compton CH, Gubb J, Nieman R, et al. 2001. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358:265-70